|
gptkbp:instanceOf
|
antiviral drug
protease inhibitor
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AE09
|
|
gptkbp:brand
|
gptkb:Aptivus
|
|
gptkbp:CASNumber
|
174484-41-4
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:eliminationHalfLife
|
4.8-6 hours
|
|
gptkbp:hasMolecularFormula
|
C31H33F3N2O5S
|
|
gptkbp:hasSMILES
|
CC(C)C1=CC(=C(C=C1)C2=NC(=CS2)C3=CC=C(C=C3)C(F)(F)F)C(=O)N4CCCCC4C(=O)O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tipranavir
|
|
gptkbp:interactsWith
|
gptkb:ritonavir
|
|
gptkbp:KEGGID
|
D06175
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits HIV-1 protease
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
602.67 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL1201192
213039
DB00932
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
rash
hepatotoxicity
|
|
gptkbp:UNII
|
Y5L2157C9T
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:bfsParent
|
gptkb:J05AE
|
|
gptkbp:bfsLayer
|
6
|